ENDRA Life Sciences (NDRA) EBITDA (2016 - 2026)

ENDRA Life Sciences (NDRA) has 11 years of EBITDA data on file, last reported at -$2.2 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$2.2 million, down 47.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.2 million (up 77.06% YoY), and the FY2025 annual result was -$1.5 million, up 86.36% from the prior year.
• EBITDA retreated to -$2.2 million in Q1 2026 per NDRA's latest filing, from $2.7 million in the prior quarter.
• Over five years, EBITDA peaked at $2.7 million in Q4 2025 and troughed at -$4.3 million in Q4 2024.
• A 5-year average of -$2.2 million and a median of -$2.8 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA tumbled 194.75% in 2024, then surged 162.03% in 2025.
• A 5-year view of EBITDA shows it stood at -$3.3 million in 2022, then surged by 56.0% to -$1.5 million in 2023, then plunged by 194.75% to -$4.3 million in 2024, then surged by 162.03% to $2.7 million in 2025, then sank by 181.56% to -$2.2 million in 2026.
• Business Quant data shows NDRA's EBITDA at -$2.2 million in Q1 2026, $2.7 million in Q4 2025, and -$1.4 million in Q3 2025.